Shares of Mankind Pharma on Friday fell around 2.5% to day\’s low of Rs 2,090 on BSE after the company announced that it has signed a definitive agreement to acquire 100% stake in Bharat Serums and Vaccines Limited (BSV) from Advent International for an enterprise value of about Rs 13,630 crore.
BSV reported revenues of Rs 1,723 crore in FY24, delivering robust 20% year-on-year (YoY) growth with adjusted EBITDA margins of 28%. The business has grown at 21% revenue CAGR over the last three years.
Mankind said that the strategic move will position it as a market leader in the Indian women\’s health and fertility drug market alongside access to other high entry barrier products in critical care with established complex R&D tech platforms.
\”We believe women’s health & fertility segment has massive opportunity along with strong growth visibility globally, led by structural tailwinds. BSV\’s established Specialty R&D Tech Platforms with complex portfolio across Women’s health, Fertility, critical care and Immunoglobulin segment perfectly aligns Mankind Pharma\’s strategic vision to expand its footprint in high entry barrier portfolio,\” said Rajeev Juneja, Vice-chairman and Managing Director, Mankind Pharma.
BSV has one of the most comprehensive portfolio in fertility segment to scale in both India and International markets amid increasing IVF penetration. It has a niche portfolio offering in Women\’s Health, encompassing the entire lifecycle – from fertility to post-pregnancy.
In the last one year, Mankind Pharma shares have rallied around 15%. Trendlyne data shows that out of 15 analysts with a coverage on the stock, a majority 10 of them have buy ratings while one analyst has a sell call. The remaining four have hold ratings on the pharma stock.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
#sr_widget.onDemand p, #stock_pro.onDemand p{font-size: 14px;line-height: 1.28;}
.onDemand .live_stock{left:17px;padding:1px 3px 1px 5px;font-size:12px;font-weight:600;line-height:18px;top:9px}
#sr_widget.onDemand .sr_desc{margin:0 auto 0;}
#sr_widget.onDemand .sr_desc{color: #024d99;margin-top:10px;}
#sr_widget.onDemand .crypto .live_stock .lb-icon{8px 6px 5px 3px !important}
#sr_widget.crypto.onDemand a.text{border-bottom:1px solid #ccc;padding-bottom:5px;display:block;width:100%}
#sr_widget.onDemand .sr_desc .text p, #stock_pro.onDemand .sr_desc .text p{font-size:12px;font-weight:400;}
#Budget 2024 with ET
New slabs announced in new income tax regime
FM \’s plan for Viksit Bharat: A look at key numbers
